Literature DB >> 10831022

Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.

C L DeVane1, J S Markowitz, S W Carson, D W Boulton, H S Gill, Z Nahas, S C Risch.   

Abstract

Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831022     DOI: 10.1097/00004714-200006000-00009

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

Review 1.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

Review 2.  Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

Authors:  Josephine Elia; Victoria L Vetter
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

3.  Effects of food on the pharmacokinetics of methylphenidate.

Authors:  K K Midha; G McKay; M J Rawson; E D Korchinski; J W Hubbard
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

4.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

Review 5.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.

Authors:  Jingcheng Xiao; Jian Shi; Brian R Thompson; David E Smith; Tao Zhang; Hao-Jie Zhu
Journal:  J Pharm Sci       Date:  2022-05-06       Impact factor: 3.784

7.  An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

Authors:  Paul Hammerness; Anna Georgiopoulos; Robert L Doyle; Linsey Utzinger; Mary Schillinger; Marykate Martelon; Kerry Brodziak; Joseph Biederman; Timothy E Wilens
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

Review 8.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates.

Authors:  Xiaoxia Yang; Suzanne M Morris; Jeffery M Gearhart; Christopher D Ruark; Merle G Paule; William Slikker; Donald R Mattison; Benedetto Vitiello; Nathan C Twaddle; Daniel R Doerge; John F Young; Jeffrey W Fisher
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

10.  Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report.

Authors:  Teerarat Tan-Kam; Chutamanee Suthisisang; Chosita Pavasuthipaisit; Penkhae Limsila; Apichaya Puangpetch; Chonlaphat Sukasem
Journal:  Pharmgenomics Pers Med       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.